Bloodstream infections (BSIs) are frequent infectious complications in neutropenic patients. In order to determine the efficacy of surveillance blood cultures (BCs) to detect BSIs prior to clinical manifestation we performed a prospective trial. One hundred patients with haematological malignancies and long-term neutropenia following intensive cytotoxic therapies were recruited. BCs were taken thrice weekly during neutropenia. Forty-two patients were diagnosed with BSI. In 18 (43%) of those patients surveillance BC results were positive and identified microorganisms prior to onset of fever. In patients with positive surveillance BCs modification of the clinical management (specific antimicrobial therapy, CVC removal) resulted in a shorter time to defervescence (median 1.5 days) compared with patients with BCs positive after onset of fever (median 3.5 days, P = 0.004). In conclusion we detected causative microorganisms in more than one-third of BSIs prior to onset of clinical manifestation. The impact of surveillance BCs on the outcome has to be assessed in randomized studies.
introduction
Bloodstream infections (BSIs) are one of the most serious complications in patients with haematological malignancies and profound neutropenia following intensive cytotoxic therapy. In this patient population BSIs are the most frequently documented microbiological infections [1] [2] [3] . BSIs are associated with severe complications such as septic shock and multi-organ failure, which are potentially life threatening, especially in immunocompromised hosts. The standard procedure for diagnosis of BSIs is to take blood cultures (BCs) at onset of fever, which is the clinical hallmark of BSIs in immune-competent hosts [4] [5] [6] , but may be absent after intensive chemotherapy or haematopoietic stem cell transplantation (HSCT) due to the anergic state of the immune system. Several clinical trials showed improved survival for immediate empirical broad-spectrum antimicrobial therapy at onset of fever, which has become the standard procedure [7] [8] [9] . Despite such an immediate approach, BSIs in neutropenic patients often cause considerable morbidity and mortality. The high mortality is partly related to BSIs with microorganisms resistant to broad-spectrum antibiotics, which are emerging in many centres [10] [11] [12] [13] . Thus, earlier detection and susceptibility testing of microorganisms causing BSIs may lead to optimization of antimicrobial therapy. In pilot studies we and others [14, 15] found that surveillance with BCs is feasible in neutropenic patients and helps in detecting significant microorganisms causing BSIs prior to the occurrence of signs of infections. Therefore we decided to perform a prospective trial with a larger number of patients and standardized diagnosis and treatment of infectious complications.
patients and methods
participants According to the study protocol 100 patients were enrolled. All patients were recruited and treated at the department of Haematology, Oncology and Transfusion Medicine in the Charité -Campus Benjamin Franklin. Adult patients ( ‡18 years) with haematological malignancies, receiving chemotherapy likely to induce long-term neutropenia (neutrophil count <500/mm 3 for >10 days) or undergoing HSCT were eligible. 
outcomes
The primary endpoint was detection of the causative infectious pathogen in BCs drawn prior to onset of clinical symptoms of BSI. Criteria used to define BSI were those of the Centres for Disease Control (CDC) [16, 17] .
In line with these definitions, BSIs were defined as isolation of a recognized pathogen from one ore more BCs that were unrelated to an infection at another site with or without fever or hypotension plus one of the following: isolation of a common skin contaminant in two separate BCs, isolation of a common skin contaminant in one BC in a patient with CVC and start of adequate antimicrobial therapy. When a pathogen was detected in surveillance BCs and the patient was diagnosed with BSI later on, the microorganism was considered to be the likely cause of the BSI under the following conditions: (i) absence of other foci of infection (e.g. pneumonia, urinary tract infection) plus detection of the same strain (with the same susceptibility pattern) in BCs at onset, or after onset, of clinical symptoms; (ii) absence of other foci of infection plus detection of the same strain (with the same susceptibility pattern) at the tip of the CVC at onset, or after onset, of clinical symptoms. The number of false-positive surveillance BC results and the antimicrobial spectrum in BCs were analysed as secondary outcome variables. BC results were considered to be possibly false positive when: (i) the patient did not present with symptoms of BSI (including clinical deterioration without fever) within 5 days after a positive surveillance BC result, or (ii) the patient presented with clinical symptoms of BSI within 5 days after a positive surveillance BC result, but the microorganism detected in the surveillance BC was not identical with infectious pathogens identified at or after onset of clinical symptoms of BSI.
supportive care and diagnostic procedures
According to the standard clinical protocol in our institution all patients received oral topical amphotericin B four times daily plus antibacterial prophylaxis with levofloxacin 500 mg/day orally. Patients were examined daily for clinical signs of infection. Two separate sets of BCs (CVC and peripheral vein) plus a urine culture were obtained in all patients who developed fever. A chest X-ray was performed 1-3 days prior to neutropenia and at onset of fever. In all patients with atypical infiltrates in the chest X-ray, high resolution CT scan and brochoscopy were performed. Patients without lung infiltrates but persisting fever despite broad-spectrum antibiotic therapy underwent high-resolution CT scan within 5 days of the onset of fever. Patients with neutropenia and FUO immediately received broad-spectrum antibiotics. All patients without known intolerance received piperacillin-tazobactam (TazobacÒ) 4.5 g three times daily. Treatment success was re-evaluated after 3 days. In cases of defervescence the regimen was continued for 7 days in total. In cases of persistent fever antibacterial therapy was changed to imipinem-cilastin (ZienamÒ) 1 g three times daily. A glycopeptide drug was added in patients with severe mucositis or suspected CVC infection. In all patients with suspected CVC infection the CVC was removed.
processing of blood cultures
Aerobic and anaerobic blood culture flasks were incubated at 37°C in a semi-automated blood culture system (BacT/Alert, bioMé rieux, Marcy l'Etoile, France) for up to 7 days. If growth was indicated, subcultures for bacteria and fungi on solid culture media incubated in an aerobic CO 2 -enriched atmosphere as well as under anaerobic conditions were set up and preliminary identification by Gram staining was made. Identification using standard microbiological methods and semi-automated identification for Gram-negative bacilli (Vitek, bioMé rieux) and susceptibility testing was performed according to DIN (Deutsches Institut für Normung) standards.
statistical analysis
Statistical analysis was performed using commercially available software (SPSS 14). Descriptives include absolute and relative frequencies for categorical data, median and range for numerical measurements (Tables 1  and 2 ). Due to the skewed distribution of time to defervescence, confirmatory comparison between patients presenting with BCs positive (Figure 1a ). Seventy-one BCs in 45 patients were positive, 22 patients had more than one positive BC result. The identified organisms in all positive BCs are listed in Table 2 . For further analysis only the first positive surveillance BC result and first diagnostic BC result were used. Of the 92 patients with fever 42 patients were diagnosed with BSI. A summary of the clinical data for the 42 patients with fever and microbiologically documented BSI is given in Table 3 .
In 18 (43%) of those patients surveillance BC results were positive and identified microorganisms prior to onset of fever. In the remaining 24 patients BCs became positive in the samples taken at onset of fever (Figure 1b) .
Three patients had positive BC results in surveillance cultures and did not present with fever as a clinical sign of BSI within the following 5 days. However, two of them were diagnosed for BSI later on. The first patient did not present with elevated temperatures: she was treated with high-dose steroids for severe graft versus host disease (GVHD) and suffered from atypical pneumonia. Stenotrophomonas maltophilia was found both in broncheo-alveolar lavage and in surveillance BCs. The second patient had temperatures up to 37.9°C and clinical deterioration. A urinary tract infection with bacteraemia and severe sepsis was diagnosed; Escherichia coli with the identical susceptibility pattern was isolated in urine cultures and in surveillance BCs. The third patient had one positive BC result with Corynebacterium sp. independently from clinical signs of infection, which was classified as 'false positive'.
Thus, for the prediction of BSI within 5 days the PPV, NPV, sensitivity and specificity of a single positive surveillance BC was 94.7%, 70.4%, 42.9% and 98.3%, respectively. For the prediction of fever associated with a diagnostic BC consistent with the surveillance BC taken within the previous 5 days the PPV, NPV, sensitivity and specificity accounted for 85.7%, 69.7%, 42.9% and 94.8%, respectively. For the prediction of fever within 5 days irrespective of a positive diagnostic BC the PPV, NPV, sensitivity and specificity was 90%, 7.5%, 19.6% and 75%, respectively. All 42 patients had positive BCs at/after onset of fever. In 18 patients surveillance BCs identified the organism causing BSI prior to onset of fever. In 24 patients BCs only became positive in diagnostic BCs at/after onset of fever.
original article Annals of Oncology defervescence in patients with BSIs and positive BCs prior to onset of fever According to the study protocol patients with detection of pathogens in surveillance BCs received specific antimicrobial therapy at onset of fever in addition to broad-spectrum antibiotics according to the standard procedure. In order to determine whether the early optimization of antimicrobial therapy according to results of positive surveillance BCs has the potential to improve clinical outcome we determined the time to defervescence in the patients with BSIs. The median time from onset of fever to defervescence was 1.5 days (range 1-6 days) and 3.5 days (range 1-18 days) in patients with BCs positive prior to onset of fever and in patients with BCs positive after onset of fever, respectively (P = 0.004, Figure 2 ).
patients with more than one positive BC result Twenty-two of the 42 patients with documented BSIs had more than one positive BC. These 22 patients with BSIs and multiple positive BCs can be assigned to one of two groups: First, the 18 patients with positive surveillance BCs also had positive diagnostic BCs with the identical pathogen at/after onset of fever. Second, there were six patients with more than one positive diagnostic BC. All BC isolates (coagulase-negative staphylococci n = 5, E. coli n = 1) of these patients were resistant to the first-line antibiotic therapy with piperacillin-tazobactam, which was started at onset of fever. In these patients antibiotic therapy was adjusted once results of susceptibility testing of diagnostic BCs were available.
patients with fever but negative BCs
There were 50 patients with fever during neutropenia but negative surveillance and diagnostic BCs. This group was clinically heterogeneous as is indicated by the diagnoses: FUO, n = 31; pneumonia, n = 14 (fungal n = 6, bacterial n = 3, unknown pathogen n = 5); urinary tract infection, n = 5. Management of these patients was according to the standard clinical protocol of our institution (see 'patients and methods') and current guidelines. The median time from onset of fever to defervescence in these patients was 3 days (range 1-17 days), which did not differ significantly from the time to defervescence of patients with proven BSIs (median 3 days, range 1-18 days).
discussion
Our trial is the first prospective evaluation showing the efficacy of surveillance BCs in detecting BSIs in patients with haematologic malignancies, which are a major clinical problem [18, 19] . In the present study we were able to detect the causative organism in a relevant percentage of patients with documented BSIs prior to onset of fever by surveillance BCs. The organisms identified prior to onset of fever were mostly Gram-positive cocci, reflecting the microbiological spectrum found in patients with antimicrobial prophylaxis for Gram-negative pathogens (here levofloxacin) [15, 20] . The majority of isolates were coagulase-negative staphylococci being indicative of systemic catheter-related infections. However, none of these patients presented with local symptoms of infection at the CVC insertion site, which is in line with previous reports that local infection is rare in catheter-related infections caused by coagulase-negative staphylococci [21] . In those patients the results of surveillance BCs enabled us to improve the clinical management: the CVCs were removed and antimicrobial therapy was optimized taking into account the results of susceptibility testing. The improved clinical management at onset of fever led to early defervescence in patients with positive surveillance BCs.
The sensitivity of surveillance BCs in detecting Gram-negative bacteraemia prior to onset of fever was low in our trial. This reflects most likely the higher virulence of these pathogens. Thus, immediate initiation of broad-spectrum antibiotic therapy, independent of surveillance BC results, at onset of neutropenic fever is mandatory should this new strategy be introduced into standard care.
A common concern of the procedure of taking surveillance BCs are false-positive results and a potential 'over-treatment' leading to drug-related side-effects and high costs [22] [23] [24] . In our study we investigated exclusively highly immunosuppressed patients with prolonged neutropenia and found a low rate of false-positive surveillance BC results. We certainly can not exclude that some of the surveillance BC results detecting coagulase-negative staphylococci were rather a sign of catheter colonization than of significant infection. However, since we found that catheter removal and start of specific antimicrobial therapy led to a shorter 
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period of fever in patients in the surveillance BC group we consider the majority of positive surveillance BC results to be 'true positive'.
Our results highlight that prospective surveillance BCs are specific and have a high predictive value for BSIs in neutropenic patients, supporting their use in guiding treatment. However, their sensitivity and negative predictive value for fever in neutropenia is low. Thus, it remains to be determined whether this approach is a cost-effective use of resources.
The impact of surveillance BCs on the outcome in neutropenic patients with BSIs has to be assessed in a randomized controlled trial. The outline design for such a study could be: randomization of patients with positive surveillance BCs to receive either (i) empirical antibiotic therapy (standard) or (ii) empirical antibiotics plus directed antimicrobial therapy according to the pathogen isolated in the surveillance BC (intervention). The key outcome measure would be the time to devervescence. Secondary outcome measurements should include survival and a cost-benefit analysis.
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